Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Study acronym: SANOVO
StatusActive, Not Recruiting
PhasePhase 3
SponsorHutchmed
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Interventions modified
  2. Sponsor changed: Hutchison Medipharma Limited to Hutchmed
    • Eligibility criteria expanded, about 35 words
  3. Primary and study completion dates: Aug 30, 2026 to May 30, 2028
    • Enrollment target: 320 to 412
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints revised (8)
    v5
  4. Primary completion date: Nov 15, 2024 to Aug 30, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 31, 2025 to Aug 30, 2026
    • Site details revised
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 31, 2021 to Sep 6, 2021
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
Trial Details
NCT Number NCT05009836
Lead Sponsor Hutchmed
Conditions
(from sponsor)		 Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 412 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov